Medical - Care Facilities
Compare Stocks
5 / 10Stock Comparison
FMS vs FXNC vs DVA vs NKSH vs CARE
Revenue, margins, valuation, and 5-year total return — side by side.
Banks - Regional
Medical - Care Facilities
Banks - Regional
Banks - Regional
FMS vs FXNC vs DVA vs NKSH vs CARE — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Care Facilities | Banks - Regional | Medical - Care Facilities | Banks - Regional | Banks - Regional |
| Market Cap | $11.92B | $253M | $12.60B | $240M | $580M |
| Revenue (TTM) | $19.36B | $112M | $13.84B | $85M | $255M |
| Net Income (TTM) | $947M | $18M | $781M | $16M | $31M |
| Gross Margin | 26.0% | 74.0% | 31.1% | 65.1% | 61.7% |
| Operating Margin | 9.7% | 19.6% | 15.0% | 22.5% | 15.7% |
| Forward P/E | 10.5x | 11.7x | 13.8x | 11.7x | 4.8x |
| Total Debt | $10.79B | $43M | $15.05B | $2M | $179M |
| Cash & Equiv. | $1.60B | $161M | $758M | $8M | $105M |
FMS vs FXNC vs DVA vs NKSH vs CARE — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Fresenius Medical C… (FMS) | 100 | 51.3 | -48.7% |
| First National Corp… (FXNC) | 100 | 210.5 | +110.5% |
| DaVita Inc. (DVA) | 100 | 242.4 | +142.4% |
| National Bankshares… (NKSH) | 100 | 122.4 | +22.4% |
| Carter Bankshares, … (CARE) | 100 | 371.0 | +271.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: FMS vs FXNC vs DVA vs NKSH vs CARE
Each card shows where this stock fits in a portfolio — not just who wins on paper.
FMS is the clearest fit if your priority is income & stability.
- Dividend streak 4 yrs, beta 0.49, yield 3.8%
FXNC ranks third and is worth considering specifically for growth exposure and long-term compounding.
- Rev growth 27.1%, EPS growth 96.0%
- 241.1% 10Y total return vs CARE's 112.9%
- NIM 3.6% vs NKSH's 2.5%
- 27.1% NII/revenue growth vs FMS's 1.5%
DVA carries the broadest edge in this set and is the clearest fit for sleep-well-at-night and valuation efficiency.
- Lower volatility, beta 0.05, current ratio 1.29x
- PEG 1.67 vs FXNC's 7.87
- PEG 1.67 vs 7.87
- Beta 0.05 vs NKSH's 0.76
NKSH is the #2 pick in this set and the best alternative if defensive is your priority.
- Beta 0.76, yield 4.0%, current ratio 1203.84x
- 18.6% margin vs FMS's 4.9%
- 4.0% yield, 1-year raise streak, vs FXNC's 2.2%, (2 stocks pay no dividend)
CARE is the clearest fit if your priority is momentum.
- +69.0% vs FMS's -20.5%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 27.1% NII/revenue growth vs FMS's 1.5% | |
| Value | PEG 1.67 vs 7.87 | |
| Quality / Margins | 18.6% margin vs FMS's 4.9% | |
| Stability / Safety | Beta 0.05 vs NKSH's 0.76 | |
| Dividends | 4.0% yield, 1-year raise streak, vs FXNC's 2.2%, (2 stocks pay no dividend) | |
| Momentum (1Y) | +69.0% vs FMS's -20.5% | |
| Efficiency (ROA) | 4.5% ROA vs CARE's 0.7%, ROIC 10.5% vs 5.7% |
FMS vs FXNC vs DVA vs NKSH vs CARE — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FMS vs FXNC vs DVA vs NKSH vs CARE — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
DVA leads in 3 of 6 categories
FXNC leads 1 • FMS leads 1 • NKSH leads 0 • CARE leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
FXNC leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
FMS is the larger business by revenue, generating $19.4B annually — 226.9x NKSH's $85M. NKSH is the more profitable business, keeping 18.6% of every revenue dollar as net income compared to FMS's 4.9%. On growth, DVA holds the edge at +6.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $19.4B | $112M | $13.8B | $85M | $255M |
| EBITDAEarnings before interest/tax | $3.5B | $25M | $2.8B | $20M | $46M |
| Net IncomeAfter-tax profit | $947M | $18M | $781M | $16M | $31M |
| Free Cash FlowCash after capex | $1.8B | $21M | $1.5B | $17M | $30M |
| Gross MarginGross profit ÷ Revenue | +26.0% | +74.0% | +31.1% | +65.1% | +61.7% |
| Operating MarginEBIT ÷ Revenue | +9.7% | +19.6% | +15.0% | +22.5% | +15.7% |
| Net MarginNet income ÷ Revenue | +4.9% | +15.8% | +5.6% | +18.6% | +12.3% |
| FCF MarginFCF ÷ Revenue | +9.1% | +18.7% | +10.8% | +17.8% | +12.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | -5.5% | — | +6.0% | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | -15.4% | +7.1% | +43.5% | +91.7% | +8.3% |
Valuation Metrics
FMS leads this category, winning 6 of 7 comparable metrics.
Valuation Metrics
At 11.0x trailing earnings, FMS trades at a 47% valuation discount to DVA's 20.6x P/E. Adjusting for growth (PEG ratio), FMS offers better value at 2.15x vs NKSH's 145.48x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $11.9B | $253M | $12.6B | $240M | $580M |
| Enterprise ValueMkt cap + debt − cash | $22.7B | $134M | $26.9B | $234M | $654M |
| Trailing P/EPrice ÷ TTM EPS | 10.96x | 14.27x | 20.64x | 15.14x | 18.71x |
| Forward P/EPrice ÷ next-FY EPS est. | 10.52x | 11.75x | 13.85x | 11.71x | 4.77x |
| PEG RatioP/E ÷ EPS growth rate | 2.15x | 9.55x | 2.49x | 145.48x | — |
| EV / EBITDAEnterprise value multiple | 5.91x | 6.13x | 9.87x | 12.20x | 16.34x |
| Price / SalesMarket cap ÷ Revenue | 0.52x | 2.25x | 0.92x | 2.81x | 2.28x |
| Price / BookPrice ÷ Book value/share | 0.75x | 1.35x | 14.93x | 1.30x | 1.40x |
| Price / FCFMarket cap ÷ FCF | 5.98x | 12.03x | 9.61x | 15.85x | 18.25x |
Profitability & Efficiency
DVA leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
DVA delivers a 59.1% return on equity — every $100 of shareholder capital generates $59 in annual profit, vs $7 for FMS. NKSH carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to DVA's 12.99x. On the Piotroski fundamental quality scale (0–9), NKSH scores 8/9 vs DVA's 5/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +6.7% | +10.0% | +59.1% | +9.0% | +7.6% |
| ROA (TTM)Return on assets | +3.0% | +0.9% | +4.5% | +0.9% | +0.7% |
| ROICReturn on invested capital | +5.6% | +7.7% | +10.5% | +8.4% | +5.7% |
| ROCEReturn on capital employed | +6.9% | +9.9% | +14.0% | +1.9% | +1.5% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 7 | 5 | 8 | 8 |
| Debt / EquityFinancial leverage | 0.76x | 0.23x | 12.99x | 0.01x | 0.43x |
| Net DebtTotal debt minus cash | $9.2B | -$118M | $14.3B | -$6M | $73M |
| Cash & Equiv.Liquid assets | $1.6B | $161M | $758M | $8M | $105M |
| Total DebtShort + long-term debt | $10.8B | $43M | $15.0B | $2M | $179M |
| Interest CoverageEBIT ÷ Interest expense | 10.17x | 0.84x | 3.54x | 0.64x | 0.39x |
Total Returns (Dividends Reinvested)
DVA leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CARE five years ago would be worth $18,721 today (with dividends reinvested), compared to $6,410 for FMS. Over the past 12 months, CARE leads with a +69.0% total return vs FMS's -20.5%. The 3-year compound annual growth rate (CAGR) favors DVA at 30.1% vs FMS's 0.7% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -7.9% | +14.6% | +71.4% | +14.2% | +34.8% |
| 1-Year ReturnPast 12 months | -20.5% | +46.9% | +36.3% | +49.7% | +69.0% |
| 3-Year ReturnCumulative with dividends | +2.2% | +110.8% | +120.0% | +55.1% | +94.7% |
| 5-Year ReturnCumulative with dividends | -35.9% | +68.7% | +54.8% | +31.9% | +87.2% |
| 10-Year ReturnCumulative with dividends | -35.1% | +241.1% | +158.1% | +51.3% | +112.9% |
| CAGR (3Y)Annualised 3-year return | +0.7% | +28.2% | +30.1% | +15.7% | +24.9% |
Risk & Volatility
DVA leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
DVA is the less volatile stock with a 0.05 beta — it tends to amplify market swings less than NKSH's 0.76 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DVA currently trades 99.6% from its 52-week high vs FMS's 71.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.49x | 0.70x | 0.05x | 0.76x | 0.56x |
| 52-Week HighHighest price in past year | $30.46 | $29.85 | $197.08 | $40.00 | $26.58 |
| 52-Week LowLowest price in past year | $20.02 | $18.31 | $101.00 | $24.74 | $15.37 |
| % of 52W HighCurrent price vs 52-week peak | +71.1% | +93.7% | +99.6% | +94.3% | +98.5% |
| RSI (14)Momentum oscillator 0–100 | 36.5 | 47.6 | 82.2 | 51.1 | 75.4 |
| Avg Volume (50D)Average daily shares traded | 527K | 80K | 801K | 50K | 276K |
Analyst Outlook
Evenly matched — FXNC and NKSH each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: FMS as "Hold", FXNC as "Buy", DVA as "Hold", NKSH as "Buy", CARE as "Buy". Consensus price targets imply 29.4% upside for FMS (target: $28) vs -24.9% for FXNC (target: $21). For income investors, NKSH offers the higher dividend yield at 4.01% vs FXNC's 2.19%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy | Hold | Buy | Buy |
| Price TargetConsensus 12-month target | $28.00 | $21.00 | $168.67 | — | $27.00 |
| # AnalystsCovering analysts | 18 | 1 | 23 | 4 | 4 |
| Dividend YieldAnnual dividend ÷ price | +3.8% | +2.2% | — | +4.0% | — |
| Dividend StreakConsecutive years of raises | 4 | 11 | 3 | 1 | 0 |
| Dividend / ShareAnnual DPS | $0.70 | $0.61 | — | $1.51 | — |
| Buyback YieldShare repurchases ÷ mkt cap | +5.5% | +0.1% | +14.2% | 0.0% | +3.4% |
DVA leads in 3 of 6 categories (Profitability & Efficiency, Total Returns). FXNC leads in 1 (Income & Cash Flow). 1 tied.
FMS vs FXNC vs DVA vs NKSH vs CARE: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is FMS or FXNC or DVA or NKSH or CARE a better buy right now?
For growth investors, First National Corporation (FXNC) is the stronger pick with 27.
1% revenue growth year-over-year, versus 1. 5% for Fresenius Medical Care AG & Co. KGaA (FMS). Fresenius Medical Care AG & Co. KGaA (FMS) offers the better valuation at 11. 0x trailing P/E (10. 5x forward), making it the more compelling value choice. Analysts rate First National Corporation (FXNC) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — FMS or FXNC or DVA or NKSH or CARE?
On trailing P/E, Fresenius Medical Care AG & Co.
KGaA (FMS) is the cheapest at 11. 0x versus DaVita Inc. at 20. 6x. On forward P/E, Carter Bankshares, Inc. is actually cheaper at 4. 8x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: DaVita Inc. wins at 1. 67x versus National Bankshares, Inc. 's 145. 48x — a reasonable growth-adjusted valuation.
03Which is the better long-term investment — FMS or FXNC or DVA or NKSH or CARE?
Over the past 5 years, Carter Bankshares, Inc.
(CARE) delivered a total return of +87. 2%, compared to -35. 9% for Fresenius Medical Care AG & Co. KGaA (FMS). Over 10 years, the gap is even starker: FXNC returned +241. 1% versus FMS's -35. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — FMS or FXNC or DVA or NKSH or CARE?
By beta (market sensitivity over 5 years), DaVita Inc.
(DVA) is the lower-risk stock at 0. 05β versus National Bankshares, Inc. 's 0. 76β — meaning NKSH is approximately 1497% more volatile than DVA relative to the S&P 500. On balance sheet safety, National Bankshares, Inc. (NKSH) carries a lower debt/equity ratio of 1% versus 13% for DaVita Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — FMS or FXNC or DVA or NKSH or CARE?
By revenue growth (latest reported year), First National Corporation (FXNC) is pulling ahead at 27.
1% versus 1. 5% for Fresenius Medical Care AG & Co. KGaA (FMS). On earnings-per-share growth, the picture is similar: National Bankshares, Inc. grew EPS 100. 8% year-over-year, compared to -11. 4% for DaVita Inc.. Over a 3-year CAGR, DVA leads at 5. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — FMS or FXNC or DVA or NKSH or CARE?
National Bankshares, Inc.
(NKSH) is the more profitable company, earning 18. 6% net margin versus 5. 0% for Fresenius Medical Care AG & Co. KGaA — meaning it keeps 18. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NKSH leads at 22. 5% versus 9. 3% for FMS. At the gross margin level — before operating expenses — FXNC leads at 74. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is FMS or FXNC or DVA or NKSH or CARE more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, DaVita Inc. (DVA) is the more undervalued stock at a PEG of 1. 67x versus National Bankshares, Inc. 's 145. 48x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Carter Bankshares, Inc. (CARE) trades at 4. 8x forward P/E versus 13. 8x for DaVita Inc. — 9. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for FMS: 29. 4% to $28. 00.
08Which pays a better dividend — FMS or FXNC or DVA or NKSH or CARE?
In this comparison, NKSH (4.
0% yield), FMS (3. 8% yield), FXNC (2. 2% yield) pay a dividend. DVA, CARE do not pay a meaningful dividend and should not be held primarily for income.
09Is FMS or FXNC or DVA or NKSH or CARE better for a retirement portfolio?
For long-horizon retirement investors, DaVita Inc.
(DVA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 05), +158. 1% 10Y return). Both have compounded well over 10 years (DVA: +158. 1%, CARE: +112. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between FMS and FXNC and DVA and NKSH and CARE?
These companies operate in different sectors (FMS (Healthcare) and FXNC (Financial Services) and DVA (Healthcare) and NKSH (Financial Services) and CARE (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: FMS is a mid-cap deep-value stock; FXNC is a small-cap high-growth stock; DVA is a mid-cap quality compounder stock; NKSH is a small-cap deep-value stock; CARE is a small-cap quality compounder stock. FMS, FXNC, NKSH pay a dividend while DVA, CARE do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.